Effects of the neoadjuvant chemotherapy of the combination application of Epirubicin and Lipid Paclitaxel in the treatment of triple negative breast cancer
WEI Wen-song
Department of the Third Galactophore,the Third Hospital of Nanchang City,Jiangxi Province,Nanchang 330009,China
Abstract:ObjectiveTo explore the clinical efficacy of the neoadjuvant chemotherapy of the combination application of Epirubicin and Lipid Paclitaxel in the treatment of triple negative breast cancer (TNBC).Methods80 patients with TNBC in our hospital from June 2015 to June 2016 were selected and randomly divided into the observation group and the control group,40 cases in each group.The control group was given simple neoadjuvant chemotherapy of Epirubicin. The observation group was given neoadjuvant chemotherapy of the combination application of Epirubicin and Lipid Paclitaxel.The tumor diameter,breast cancer susceptibility gene(BRCA1)level,fork-box protein A1(FOXA1)level before and after treatment and clinical efficacy,the incidence rate of adverse reaction were compared between the two groups.ResultsThe total effective rate of the observation group was 82.50%,which was higher than 70.00%of the control group,with significant difference (P<0.05).There was no significant difference in the incidence rate of adverse reaction between the two groups(P>0.05).The tumor diameter,the level of BRCA1 and FOXA1 after treatment in the two group was lower than that before treatment,with significant difference (P<0.05).The tumor diameter,the level of BRCA1 and FOXA1 after treatment in the observation group was better than that in the control group,with significant difference(P<0.05).ConclusionThe neoadjuvant chemotherapy of the combination application of Epirubicin and Lipid Paclitaxel in the treatment of TNBC is safe and reliable,with no increase of adverse reaction,and the patients have a higher degree of tolerance while being treated.It is highly significant in clinical application.
魏文嵩. 表柔比星联合紫杉醇脂质体的新辅助化疗方法治疗三阴性乳腺癌的效果[J]. 中国当代医药, 2016, 23(35): 65-68.
WEI Wen-song. Effects of the neoadjuvant chemotherapy of the combination application of Epirubicin and Lipid Paclitaxel in the treatment of triple negative breast cancer. 中国当代医药, 2016, 23(35): 65-68.